Skip to main content

Yang Zhou wins grant from the HPS Network and ATS Foundation

Oct. 1, 2011



Contact: Donna Appell, President and Founder, HPS Network, (516) 922-4022, or e-mail: dappell@hpsnetwork.org






FOR IMMEDIATE RELEASE






Yang Zhou wins grant from the HPS Network and ATS Foundation






Oyster Bay, N.Y. – Dr. Yang Zhou, associate research scientist working in Dr. Jack Elias’s lab at the Yale University School of Medicine, has been awarded a grant from the Hermansky-Pudlak Syndrome Network (HPS Network) and the American Thoracic Society Foundation.






Dr. Zhou’s project will investigate a potential biomarker and therapeutic target of pulmonary fibrosis, which may one day lead to better diagnostic and treatment options for patients. Hermansky-Pudlak Syndrome (HPS) is a rare genetic disorder that causes albinism, a bleeding disorder, and in a subset of patients, other health problems such as a Crohn’s-like digestive problem and pulmonary fibrosis. Pulmonary fibrosis is a scarring of the lungs. In patients with HPS, it is ultimately fatal, typically between 30 and 50 years of age. While HPS is rare, it is one of the most common genetic disorders among people of Puerto Rican ancestry.






The HPS Network and the ATS Foundation have partnered to provide the funding for this two-year grant as part of the ATS’s Foundation Research Program.






The HPS Network is a not-for-profit organization, founded in 1992, that offers support to families affected by HPS as well as promotes HPS research. Learn more at: www.hpsnetwork.org.






The ATS Foundation strives to preserve and improve the respiratory health of all people globally through its strategic investments in the full spectrum of research, education and training. The Foundation measures the success of its efforts by the benefits provided to patients, their families and communities worldwide. Learn more at: http://foundation.thoracic.org/






###






Labels:

Comments

Post a Comment

Popular posts from this blog

Ratner's Cheesecake

Here's another recipe from Toby! Thanks Toby......and I'll get the others posted soon! Ratner's Cheesecake and plain cookies Ratner's was a Jewish dairy restaurant in the lower East Side of Manhattan. This recipe, from my disintegrating, no longer in print Ratner's cookbook, is the closest I've ever gotten to reproducing the rich, heavy cheesecake my mother made when I was a kid. It's worth the time it takes to prepare and every last calorie. Dough Can be prepared in advance. Makes enough for two cakes. Can be frozen or used to make cookies – see recipe below. 1 cup sugar 1 teaspoon vanilla extract 1 cup shortening 1 teaspoon lemon extract 1 cup butter 2 eggs 3 cups sifted cake flour ½ teaspoon salt 2 cups all purpose flour 1 teaspoon baking powder 1. In a bowl, combine all ingredients with hands. Refrigerate 3 -4 hours, or preferably overnight. Filling (for
1 comment
Read more

The next generation with Hermansky-Pudlak Syndrome

I'm so behind on posting about the trip to Puerto Rico. Since the episode of Mystery Diagnosis on Hermansky-Pudlak Syndrome ran right after we got home, it's been a little busy. These, however, are my favorite pictures from Puerto Rico. I know, not pretty senery etc - but these little guys and gals inspire me. They are the next generation of folks with HPS, and if we keep up the hard work, they will live better lives because of it. They motivate me.
Post a Comment
Read more

Some good news about Pirfenidone

Below is a press release from Intermune, the company that makes Pirfenidone. They have essentially reviewed the various clinical trials going on, and decided that Pirfenidone is safe and well tolerated. That would pretty much go along with what we've observed in the HPS community as well. We have a few folks that have been on the drug since the late 90s and continue to do well. Of course, as a journalist, I do have to say consider the source - but at the same time, as someone in a Pirfenidone trial, it's good to know. Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting - Analysis shows safety and tolerability of pirfenidone across four clinical trials - VIENNA, Sept. 14 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN ) today announced that the results of a comprehensive review of safety data from four clinical studies were presented at the 2009 European Respiratory Society Annual Congress in Vienna, Austria
Post a Comment
Read more